Insights into the role of complement regulatory proteins in HPV mediated cervical carcinogenesis

Ingber, 2008, Can cancer be reversed by engineering the tumor microenvironment?, Semin. Cancer Biol., 18, 356, 10.1016/j.semcancer.2008.03.016 Nejo, 2018, Prevalence and risk factors for genital human papillomavirus infections among women in Southwest Nigeria, Arch Basic Appl Med, 6, 105 Sreedevi, 2015, Epidemiology of cervical cancer with special focus on India, Int. J. Womens Health, 7, 405 Thulaseedharan, 2012, Socio demographic and reproductive risk factors for cervical cancer - a large prospective cohort study from rural India, Asian Pac. J. Cancer Prev., 13, 2991, 10.7314/APJCP.2012.13.6.2991 Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394, 10.3322/caac.21492 Singh, 2013, Downregulation of tumor suppressor gene PML in uterine cervical carcinogenesis: impact of human papillomavirus infection (HPV), Gynecol. Oncol., 128, 420, 10.1016/j.ygyno.2012.11.041 Bharti, 2010, Human papillomavirus and control of cervical cancer in India, Expert Rev. Obstet. Gynecol., 5, 329, 10.1586/eog.10.23 Gupta, 2018, HPV: molecular pathways and targets, Curr. Probl. Cancer, 42, 161, 10.1016/j.currproblcancer.2018.03.003 Das, 2008, Prospects and prejudices of human papillomavirus vaccines in India, Vaccine, 26, 2669, 10.1016/j.vaccine.2008.03.056 Kohaar, 2009, Association between human leukocyte antigen class II alleles and human papillomavirus-mediated cervical cancer in Indian women, Hum. Immunol., 70, 222, 10.1016/j.humimm.2009.01.003 Dillner, 2007, Translational Mini-Review Series on Vaccines:monitoring of human papillomavirus vaccination, Clin. Exp. Immunol., 148, 199, 10.1111/j.1365-2249.2007.03384.x Kolev, 2014, Complement — tapping into new sites and effector systems, Nat. Rev. Immunol., 14, 811, 10.1038/nri3761 Roumenina, 2019, Context-dependent roles of complement in cancer, Nat. Rev. Cancer, 19, 698, 10.1038/s41568-019-0210-0 Merle, 2015, Complement system part II: role in immunity, Front. Immunol., 6, 257, 10.3389/fimmu.2015.00257 Afshar-Kharghan, 2017, The role of the complement system in cancer, J. Clin. Invest., 127, 780, 10.1172/JCI90962 Gilaberte, 2016, Anatomy and function of the skin, 1 Wang, 2009, Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes, Genes Dev., 23, 181, 10.1101/gad.1735109 Richmond, 2014, Immunology and skin in health and disease, Cold Spring Harb. Perspect. Med., 4, 10.1101/cshperspect.a015339 Wang, 2010, Interaction of syndecan and α6β4 integrin cytoplasmic domains: REGULATION OF ErbB2-MEDIATED INTEGRIN ACTIVATION*, J. Biol. Chem., 285, 13569, 10.1074/jbc.M110.102137 Stanley, 2012, Epithelial cell responses to infection with human papillomavirus, Clin. Microbiol. Rev., 25, 215, 10.1128/CMR.05028-11 Yoon, 2001, α6 integrin is the main receptor of human papillomavirus type 16 VLP, Biochem. Biophys. Res. Commun., 283, 668, 10.1006/bbrc.2001.4838 McBride, 2008, Replication and partitioning of papillomavirus genomes, Adv. Virus Res., 72, 155, 10.1016/S0065-3527(08)00404-1 Reinson, 2015, The cell cycle timing of human papillomavirus DNA replication, PLoS One, 10, 10.1371/journal.pone.0131675 Schiller, 2010, Current understanding of the mechanism of HPV infection, Gynecol. Oncol., 118, S12, 10.1016/j.ygyno.2010.04.004 Doorbar, 1991, Specific interaction between HPV-16 E1–E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network, Nature, 352, 824, 10.1038/352824a0 Milde-Langosch, 2000, Association of human papillomavirus infection with carcinoma of the cervix uteri and its precursor lesions: theoretical and practical implications, Virchows Arch., 437, 227, 10.1007/s004280000234 McMurray, 2001, Biology of human papillomaviruses, Int. J. Exp. Pathol., 82, 15, 10.1046/j.1365-2613.2001.00177.x Hausen, 1982, Human genital cancer: synergism between two virus infections or synergism between a virus infection and initiating events?, Lancet, 320, 1370, 10.1016/S0140-6736(82)91273-9 Narisawa-Saito, 2007, Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins, Cancer Sci., 98, 1505, 10.1111/j.1349-7006.2007.00546.x Parfenov, 2014, Characterization of HPV and host genome interactions in primary head and neck cancers, Proc Natl Acad Sci U S A, 111, 15544, 10.1073/pnas.1416074111 Thorland, 2000, Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites, Cancer Res., 60, 5916 Gao, 2017, Common fragile sites (CFS) and extremely large CFS genes are targets for human papillomavirus integrations and chromosome rearrangements in oropharyngeal squamous cell carcinoma, Genes Chromosomes Cancer, 56, 59, 10.1002/gcc.22415 Kadaja, 2009, Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses, PLoS Pathog., 5, 10.1371/journal.ppat.1000397 Kadaja, 2007, Genomic instability of the host cell induced by the human papillomavirus replication machinery, EMBO J., 26, 2180, 10.1038/sj.emboj.7601665 Badaracco, 2002, HPV16 and HPV18 in genital tumors: significantly different levels of viral integration and correlation to tumor invasiveness, J. Med. Virol., 67, 574, 10.1002/jmv.10141 Romanczuk, 1992, Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity, Proc Natl Acad Sci U S A, 89, 3159, 10.1073/pnas.89.7.3159 Buitrago-Pérez, 2009, Molecular signature of HPV-Induced carcinogenesis: pRb, p53 and gene expression profiling, Curr. Genomics, 10, 26, 10.2174/138920209787581235 Howes, 1994, Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53, Genes Dev., 8, 1300, 10.1101/gad.8.11.1300 Linke, 1996, A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage, Genes Dev., 10, 934, 10.1101/gad.10.8.934 Weinberg, 1995, The retinoblastoma protein and cell cycle control, Cell, 81, 323, 10.1016/0092-8674(95)90385-2 Moody, 2010, Human papillomavirus oncoproteins: pathways to transformation, Nat. Rev. Cancer, 10, 550, 10.1038/nrc2886 Huh, 2007, Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor, J. Virol., 81, 9737, 10.1128/JVI.00881-07 Shehata, 2005, Rel/Nuclear factor-kappa B apoptosis pathways in human cervical cancer cells, Cancer Cell Int., 5, 10, 10.1186/1475-2867-5-10 Nakayama, 2003, Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin, Cancer Lett., 192, 227, 10.1016/S0304-3835(02)00686-9 Ferrer, 2003, Signaling of cell death and cell survival following focal cerebral ischemia: life and death struggle in the Penumbra, J. Neuropathol. Exp. Neurol., 62, 329, 10.1093/jnen/62.4.329 Shreya, 2007, Mechanisms used by human papillomaviruses to escape the host immune response, Curr. Cancer Drug Targets, 7, 79, 10.2174/156800907780006869 Araibi, 2004, Downregulation of major histocompatibility complex class I in bovine papillomas, J. Gen. Virol., 85, 2809, 10.1099/vir.0.80128-0 Shukla, 2009, Infection of human papillomaviruses in cancers of different human organ sites, Indian J. Med. Res., 130, 222 Khodabandehlou, 2019, Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins, BMC Cancer, 19, 61, 10.1186/s12885-019-5286-0 de Oliveira, 2018, Presence and activity of HPV in primary lung cancer, J. Cancer Res. Clin. Oncol., 144, 2367, 10.1007/s00432-018-2748-8 Scinicariello, 2021 Syrjänen, 2002, HPV infections and oesophageal cancer, J. Clin. Pathol., 55, 721, 10.1136/jcp.55.10.721 Cocuzza, 2017, Human papillomavirus DNA detection in plasma and cervical samples of women with a recent history of low grade or precancerous cervical dysplasia, PLoS One, 12, e0188592, 10.1371/journal.pone.0188592 Pornthanakasem, 2001, Human papillomavirus DNA in plasma of patients with cervical cancer, BMC Cancer, 1, 10.1186/1471-2407-1-2 Cladel, 2019, Papillomavirus can be transmitted through the blood and produce infections in blood recipients: evidence from two animal models, Emerg. Microbes Infect., 8, 1108, 10.1080/22221751.2019.1637072 Hussain, 2009, Transcription factor AP-1 in esophageal squamous cell carcinoma: alterations in activity and expression during Human Papillomavirus infection, BMC Cancer, 9, 329, 10.1186/1471-2407-9-329 Brennan, 2021, Epidemiologic factors in patients with advanced head and neck cancer treated with radiation therapy, Head Neck, 43, 164, 10.1002/hed.26468 Whitmarsh, 2021, Survival advantage in patients with human papillomavirus‐driven oropharyngeal cancer and variation by demographic characteristics and serologic response: findings from Head and Neck 5000, Cancer, 10.1002/cncr.33505 Mishra, 2006, Differential expression and activation of NF-κB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection, Int. J. Cancer, 119, 2840, 10.1002/ijc.22262 Huh, 2007, Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor, J. Virol., 81, 9737, 10.1128/JVI.00881-07 Xu, 2001, Structural biology of the alternative pathway convertase, Immunol. Rev., 180, 123, 10.1034/j.1600-065X.2001.1800111.x Sørensen, 2005, Mannan-binding-lectin-associated serine proteases, characteristics and disease associations, Springer Semin. Immunopathol., 27, 299, 10.1007/s00281-005-0006-z Holers, 2014, Complement and Its Receptors: New Insights into Human Disease, Annu. Rev. Immunol., 32, 433, 10.1146/annurev-immunol-032713-120154 Matthews, 2004, Carboxypeptidase N: a pleiotropic regulator of inflammation, Mol. Immunol., 40, 785, 10.1016/j.molimm.2003.10.002 Zipfel, 2009, Complement regulators and inhibitory proteins, Nat. Rev. Immunol., 9, 729, 10.1038/nri2620 Geller, 2019, The role of membrane bound complement regulatory proteins in tumor development and Cancer immunotherapy, Front. Immunol., 10, 10.3389/fimmu.2019.01074 Ellison, 2007, Complement susceptibility in glutamine deprived breast cancer cells, Cell Div., 2, 10.1186/1747-1028-2-20 Jurianz, 1999, Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2, Immunopharmacology, 42, 209, 10.1016/S0162-3109(99)00006-5 Cheung, 1988, Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro, J. Clin. Invest., 81, 1122, 10.1172/JCI113426 Simpson, 1997, Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease, Am. J. Pathol., 151, 1455 An, 2016, Complement C5a induces PD-L1 expression and acts in synergy with LPS through Erk1/2 and JNK signaling pathways, Sci. Rep., 6, 10.1038/srep33346 Elmore, 2007, Apoptosis: a review of programmed cell death, Toxicol. Pathol., 35, 495, 10.1080/01926230701320337 Markiewski, 2009, Is complement good or bad for cancer patients? A new perspective on an old dilemma, Trends Immunol., 30, 286, 10.1016/j.it.2009.04.002 Ricklin, 2010, Complement: a key system for immune surveillance and homeostasis, Nat. Immunol., 11, 785, 10.1038/ni.1923 Xie, 2020, Complement membrane attack complex: new roles, mechanisms of action, and therapeutic targets, Am. J. Pathol., 190, 1138, 10.1016/j.ajpath.2020.02.006 Rich, 2000, Defying death after DNA damage, Nature, 407, 777, 10.1038/35037717 Hengartner, 2000, The biochemistry of apoptosis, Nature, 407, 770, 10.1038/35037710 Savill, 2000, Corpse clearance defines the meaning of cell death, Nature, 407, 784, 10.1038/35037722 Meier, 2000, Apoptosis in development, Nature, 407, 796, 10.1038/35037734 Fishelson, 2003, Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors, Mol. Immunol., 40, 109, 10.1016/S0161-5890(03)00112-3 Gancz, 2009, Cancer resistance to complement-dependent cytotoxicity (CDC): problem-oriented research and development, Mol. Immunol., 46, 2794, 10.1016/j.molimm.2009.05.009 Bulla, 2016, C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation, Nat. Commun., 7, 10346, 10.1038/ncomms10346 Kurihara, 2010, C5a promotes migration, proliferation, and vessel formation in endothelial cells, Inflamm. Res., 59, 659, 10.1007/s00011-010-0178-4 Perianayagam, 2002, C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathway, Kidney Int., 61, 456, 10.1046/j.1523-1755.2002.00139.x Canales, 2014, A1BG and C3 are overexpressed in patients with cervical intraepithelial neoplasia III, Oncol. Lett., 8, 939, 10.3892/ol.2014.2195 Cao, 2012, Human colonic epithelial cells detect and respond to C5a via apically expressed C5aR through the ERK pathway, Am J Physiol Cell Physiol., 302, C1731, 10.1152/ajpcell.00213.2011 Markiewski, 2008, Modulation of the antitumor immune response by complement, Nat. Immunol., 9, 1225, 10.1038/ni.1655 Connolly, 2003, Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer, Cancer Res., 63, 1389 Nunez-Cruz, 2012, Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization, Neoplasia, 14, 994, 10.1593/neo.121262